- Sona Nanotech (SONA) has announced it has received approval from the research ethics board for its clinical trial of Sona Saliva C-19
- The testing is expected to begin next week and will test up to 500 emergency room patients who may have COVID-19
- The trial will take place in tandem with a partnership with the Humber River Hospital in Toronto
- Following the study, third party analytical validation studies will be commissioned for additioal data for futre regulatory submissions
- Shares of Sona Nanotech were up 6.59 per cent to C$1.94 as of 2:52 p.m. EDT
Sona Nanotech (SONA) has announced it has received approval from the research ethics board to begin its clinical trial of Sona Saliva C-19.
Through a partnership with Humber River Hospital in Toronto, the trial is expected to begin sometime next week and aims to test 500 patients in emergency rooms who are suspected of having COVID-19.
“With the third wave now upon us, frequent rapid testing is crucial to identify COVID-19, limit spread, and decrease hospitalizations,” Dr. David Jacobs, clinical trial principal investigator at Humber River Hospital, said in a release.
Dr. Jacobs continued,
“This clinical trial is an important step in exploring the use of devices that are both more comfortable for the patient and safer for those administering the tests to ensure rapid and accurate diagnosis. Our primary concern will always be the proper care and treatment of our patients, and the safety of our front-line emergency room staff.”
Sona Nanotech is a nanotechnology and life sciences company that has developed a wide range of proprietary methods in the creation of various kinds of gold nanoparticles.
Humber River Hospital is the first digital hospital in North America and the first hospital to integrate a Command Centre with a focus on patient flow and patient safety.
Shares of Sona Nanotech were up 6.59 per cent to C$1.94 as of 2:52 p.m. EDT.
